Patent ID: 8106069

Claim:
A method for inhibiting protein kinase activity of a kinase selected from the group consisting of cdk2/cyclin A, E, B1, D1, MAPK, EGFR, PKA, Cdk5/p25, IGF1-R, Aurora-2 or Cdc7/dbf4, ACK1, BRK, JAK2, MELK MPS1, NEK6, PDGFR, PDK1, PLK1, RET, ABL, AKT1, AKT2, AKT3, AUR2, IGFR1, IR, LCK, and combinations thereof, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) wherein R is selected from the group consisting of —R a , —COR a , —CONR a R b , —SO 2 R a or —COOR a ; R 1 is a group —NR c R d or —OR c ; wherein R a , R b , R c and R d , are the same or different, and are each independently hydrogen or a group optionally further substituted, selected from straight or branched C 1 -C 6 alkyl, C 2 -C 6 straight or branched alkenyl, straight or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl or cycloalkyl C 1 -C 6 alkyl, aryl or aryl C 1 -C 6 alkyl, or heterocycle or heterocycle C 1 -C 6 alkyl or, taken together with the nitrogen atom to which they are bonded, either R a and R b as well as R c and R d can form an optionally substituted 4 to 7 membered heterocycle, optionally containing one additional ring heteroatom or heteroatomic group selected from S, O, N or NH; or isomers, tautomers or a pharmaceutically acceptable salt thereof.